Cushing's Syndrome Clinical Trial
Official title:
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.
Cushing's disease (CD) is a disorder of chronic glucocorticoid (GC) excess that gives rise to a constellation of metabolic comorbidities and to a distinct lipodystrophic body habitus characterized by central adiposity, extremity wasting, and the accumulation of supraclavicular (SC) and dorsocervical (DC) fat in the region where human brown and beige adipose tissue is known to be concentrated. In spite of the recognized thermogenic capacity of select cervical adipocytes, the potential impact of lipomatous alterations in this depot on energy balance and metabolism in CD is unknown. To our knowledge, the "buffalo hump" and the supraclavicular fat pads - which are a sensitive physical finding for CD, have never been phenotypically characterized and the mechanisms underlying the GC mediated development of fat in these depots and the associated metabolic complications have not been explored in humans. The proposed research will advance our understanding of Cushing's lipodystrophy and its metabolic complications. Furthermore, it may lead to the identification of novel mediators and targetable pathways to attenuate the adverse effects of hypercortisolism on body composition and metabolism in CD, as well as in the significant population of patients treated with chronic GCs for an array of other clinical conditions. These findings may have important implications not only for those with Cushing's disease, but for the millions of Americans who are treated with chronic glucocorticoids for an array of clinical conditions. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02468193 -
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
|
Phase 2 | |
| Recruiting |
NCT00457587 -
Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma
|
||
| Completed |
NCT00006278 -
Study of Cushing's Syndrome Not Related to ACTH Production
|
N/A | |
| Completed |
NCT00361777 -
Diagnostic Performance of Screening Tests for Cushing s Syndrome
|
||
| Active, not recruiting |
NCT03606408 -
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
|
Phase 2 | |
| Completed |
NCT02663609 -
Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome
|
||
| Recruiting |
NCT01504555 -
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
|
Phase 3 | |
| Active, not recruiting |
NCT00004343 -
Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome
|
N/A | |
| Completed |
NCT02922257 -
Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery
|
||
| Completed |
NCT01371565 -
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
|
Phase 3 | |
| Terminated |
NCT00422201 -
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion
|
Phase 2 | |
| Completed |
NCT00001180 -
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
|
N/A | |
| Completed |
NCT02804750 -
Study to Evaluate CORT125134 in Participants With Cushing's Syndrome
|
Phase 2 | |
| Completed |
NCT00936741 -
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
|
Phase 3 | |
| Recruiting |
NCT00004334 -
Study of Depression, Peptides, and Steroids in Cushing's Syndrome
|
N/A | |
| Completed |
NCT01959711 -
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
|
Phase 4 | |
| Completed |
NCT05633953 -
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
|
||
| Completed |
NCT02889224 -
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
|
N/A | |
| Terminated |
NCT00796783 -
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
|
N/A | |
| Recruiting |
NCT02019706 -
Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome
|
Phase 2 |